Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
Express Scripts
US Department of Justice
Cantor Fitzgerald
Boehringer Ingelheim

Generated: July 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,872,728

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,872,728 protect, and when does it expire?

Patent 6,872,728 protects ORILISSA and is included in one NDA.

This patent has eighteen patent family members in fourteen countries.

Summary for Patent: 6,872,728
Title: Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Abstract:GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR1## wherein A, Q, R.sub.1, R.sub.2, R.sub.3a, R.sub.3b, R.sub.4, R.sub.5, R.sub.6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Inventor(s): Zhu; Yun-Fei (San Diego, CA), Chen; Chen (San Diego, CA), Tucci; Fabio C. (San Diego, CA), Guo; Zhiqiang (San Diego, CA), Gross; Timothy D. (San Diego, CA), Rowbottom; Martin (La Jolla, CA), Struthers; R. Scott (Encinitas, CA)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:10/361,144
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,872,728
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 6,872,728

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie Inc ORILISSA elagolix sodium TABLET;ORAL 210450-001 Jul 23, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Abbvie Inc ORILISSA elagolix sodium TABLET;ORAL 210450-002 Jul 23, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Fish and Richardson
Boehringer Ingelheim
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.